TODAY'S HEADLINES

6 facts to know about the new psoriasis drug

FDA approved ixekizumab (Taltz, Eli Lilly and Company) injection for the treatment of moderate-to-severe plaque psoriasis. Here are the top 6 facts to know about Taltz. Read more

FDA approves Bayer hemophilia A drug

FDA recently approved antihemophilic factor VIII (recombinant) (Kovaltry, Bayer) for the treatment of hemophilia A in children and adults. Read more

CONTINUING PHARMACY EDUCATION

Part 2: Law: Educating and empowering patients and caregivers: The pharmacist's role in reducing the risk of opioid overdose

This month's CE activity is open for pharmacists and pharmacy technicians. "Part II: Law: Educating and empowering patients and caregivers: The pharmacist's role in reducing the risk of opioid overdose." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

FDA expands use of lung cancer drug

FDA has extended approval of crizotinib (Xalkori, Pfizer) for the treatment of certain patients with non-small cell lung cancer (NSCLC). More on cost

April 01, 2016

Related Articles

Rheumatoid arthritis drug may benefit atopic dermatitis patients

FDA OKs modified antihemophilic factor for hemophilia A